

# Sclerostin linked to vascular disease in type 2 diabetes

28 January 2013




Image courtesy of Blausen Medical

Circulating levels of the Wnt/ $\beta$ -catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in *Diabetes Care*.

(HealthDay)—Circulating levels of the Wnt/ $\beta$ -catenin signaling inhibitor sclerostin are higher in patients with type 2 diabetes who also have atherosclerotic disease, according to a study published online Jan. 3 in *Diabetes Care*.

Noting that Wnt/ $\beta$ -catenin signaling is related to the pathology of various diseases, Sonia Morales-Santana, Ph.D., from the Hospital Universitario San Cecilio in Granada, Spain, and colleagues measured serum sclerostin levels in 78 patients with [type 2 diabetes](#) mellitus, of whom 44 had atherosclerotic disease.

The researchers found that patients with atherosclerotic disease had significantly higher serum sclerostin levels, with a 4 percent increase in the risk of atherosclerotic disease for each 1 pmol/L increase in sclerostin. A sclerostin cut-off of 42.3 pmol/L could detect an increased risk of atherosclerotic disease with a sensitivity of 69 percent and a specificity of 54.8 percent. Higher sclerostin levels were associated with abnormal intima-media thickness and aortic calcification in both men and women, and with carotid plaques in men only. Homocysteine levels and intima-media thickness were positively correlated with sclerostin.

"Circulating sclerostin is increased in [type 2 diabetes mellitus](#) patients with [atherosclerotic lesions](#)," Morales-Santana and colleagues conclude.

**More information:** [Abstract](#)  
[Full Text \(subscription or payment may be required\)](#)

[Health News](#) Copyright © 2013 [HealthDay](#). All rights reserved.

APA citation: Sclerostin linked to vascular disease in type 2 diabetes (2013, January 28) retrieved 30 July 2022 from

<https://medicalxpress.com/news/2013-01-sclerostin-linked-vascular-disease-diabetes.html>

*This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.*